Alignment Healthcare: 2Q Results Beat But Incremental Back Half Investments Likely to Weigh in Near-Term

Research evidence excerpt

Alignment Healthcare: 2Q Results Beat But Incremental Back Half Investments Likely to Weigh in Near-Term

Global Research

30 July 2026ab

Alignment Healthcare Equities

United States2Q Results Beat But Incremental Back Half

Investments Likely to Weigh in Near-Term Healthcare Providers

12-month rating Neutral *

12m price target US$22.00Back Half Investment Surprise Creates Noise Despite Strong 2Q

ALHC's 2Q26 results came in better than expected as the company alluded to at an

investor conference in June and mirrors positive trends from peers. However, the back Price (30 Jul 2026) US$18.61

half guidance raised question marks with guidance coming in below on both GP and RIC: ALHC.O BBG: ALHC US

EBITDA, alongside variability between 3Q/4Q which breaks from historical trends. Our

sense is positioning was skewed to the positive given commentary from peers on MA Trading data and key metrics

and what seems to be an improving trend backdrop relative to expectations, and the 52-wk range US$24.56-12.97

back half guidance will likely create volatility. ALHC pointed to incremental clinical and Market cap. US$4.00b

G&A investments in the double digit million range for 2H as the driver, which, while Shares o/s 215m (COM)

consistent with the overarching ALHC strategy, is a surprise for investors. Beyond 2026, Free float 40%

we think there may likely be further incremental investments, particularly as 2028 is Avg. daily volume ('000) 6,040

being framed as the bigger growth year (ALHC pointed to state expansions), relative to Avg. daily value (m) US$114.8

2027. All said, we believe the strategic rationale of the investments makes sense, but Common s/h equity (12/26E) US$0.29b

there will likely be near-term volatility in the stock as ALHC lays the foundation for P/BV (12/26E) 13.7x